Loading…

Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review

Intravenous loop diuretics are widely used to treat the symptoms and signs of fluid overload in acute heart failure (AHF). Although diuretic therapy is widely used and strongly recommended by most recent clinical guidelines, prospective studies and randomized clinical trials are lacking and so relia...

Full description

Saved in:
Bibliographic Details
Published in:Heart failure reviews 2014-03, Vol.19 (2), p.237-246
Main Authors: Leto, Laura, Aspromonte, Nadia, Feola, Mauro
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c438t-31f6489519fc094967d1dc269bc8738d84c6350b2a030a105d324aabb7d6f6393
cites cdi_FETCH-LOGICAL-c438t-31f6489519fc094967d1dc269bc8738d84c6350b2a030a105d324aabb7d6f6393
container_end_page 246
container_issue 2
container_start_page 237
container_title Heart failure reviews
container_volume 19
creator Leto, Laura
Aspromonte, Nadia
Feola, Mauro
description Intravenous loop diuretics are widely used to treat the symptoms and signs of fluid overload in acute heart failure (AHF). Although diuretic therapy is widely used and strongly recommended by most recent clinical guidelines, prospective studies and randomized clinical trials are lacking and so reliable evidence is missing about the best therapy in terms of doses and methods of administration. In addition, clinical efficacy and safety outcomes are often affected by the presence of contrasting evidence. The efficacy of loop diuretics is impaired by diuretic resistance characterized by a decreased diuretic and natriuretic effect. This review focuses on the current management of AHF with diuretic therapy. Continuous diuretic infusion seems to be a good choice, from a pharmacokinetic point of view, when fluid overload is refractory to conventional therapy. Some available evidence comparing bolus injection to continuous infusion of loop diuretics proved the latter to be an effective and safe method of administration. Continuous infusion seems to produce a constant plasmatic concentration of drug with a more uniform daily diuretic and natriuretic effect and a greater safety profile (fewer adverse events such as worsening renal failure, electrolyte imbalances, ototoxicity). The analyses of the published studies did not provide conclusive data about the effects on clinical outcomes (mortality, rate of hospital readmissions, length of hospital stay and adverse events). Furthermore, recent studies focus their attention on alternative strategies of fluid removal, such as vasopressin antagonists, adenosine antagonists and ultrafiltration but available data are often inconclusive.
doi_str_mv 10.1007/s10741-012-9354-7
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1498275251</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3219692821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-31f6489519fc094967d1dc269bc8738d84c6350b2a030a105d324aabb7d6f6393</originalsourceid><addsrcrecordid>eNp1kMtKxDAUhoMozjj6AG4k4Lqaa9O4k2G8wIAbXYc0F6dDp61Jq_TtzdBR3Lg6B873_wc-AC4xusEIiduIkWA4Q5hkknKWiSMwx1zQTFBCjtNOC5IxzMQMnMW4RQgxydApmBGKKSeomAO78r4y2oxQNxZG7V0_wtbDum07aKshuL4ysN-4oLsRVg3UZugdtM60u841UffOwo3ToYdeV3Xi76CGpq6a1FrD4D4r93UOTryuo7s4zAV4e1i9Lp-y9cvj8_J-nRlGiz6j2OeskBxLb5BkMhcWW0NyWZpC0MIWzOSUo5JoRJHGiFtKmNZlKWzucyrpAlxPvV1oPwYXe7Vth9CklwozWRDBCceJwhNlQhtjcF51odrpMCqM1N6rmryq5FXtvSqRMleH5qHcOfub-BGZADIBMZ2adxf-vP639RvVR4JL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1498275251</pqid></control><display><type>article</type><title>Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review</title><source>Springer Link</source><creator>Leto, Laura ; Aspromonte, Nadia ; Feola, Mauro</creator><creatorcontrib>Leto, Laura ; Aspromonte, Nadia ; Feola, Mauro</creatorcontrib><description>Intravenous loop diuretics are widely used to treat the symptoms and signs of fluid overload in acute heart failure (AHF). Although diuretic therapy is widely used and strongly recommended by most recent clinical guidelines, prospective studies and randomized clinical trials are lacking and so reliable evidence is missing about the best therapy in terms of doses and methods of administration. In addition, clinical efficacy and safety outcomes are often affected by the presence of contrasting evidence. The efficacy of loop diuretics is impaired by diuretic resistance characterized by a decreased diuretic and natriuretic effect. This review focuses on the current management of AHF with diuretic therapy. Continuous diuretic infusion seems to be a good choice, from a pharmacokinetic point of view, when fluid overload is refractory to conventional therapy. Some available evidence comparing bolus injection to continuous infusion of loop diuretics proved the latter to be an effective and safe method of administration. Continuous infusion seems to produce a constant plasmatic concentration of drug with a more uniform daily diuretic and natriuretic effect and a greater safety profile (fewer adverse events such as worsening renal failure, electrolyte imbalances, ototoxicity). The analyses of the published studies did not provide conclusive data about the effects on clinical outcomes (mortality, rate of hospital readmissions, length of hospital stay and adverse events). Furthermore, recent studies focus their attention on alternative strategies of fluid removal, such as vasopressin antagonists, adenosine antagonists and ultrafiltration but available data are often inconclusive.</description><identifier>ISSN: 1382-4147</identifier><identifier>EISSN: 1573-7322</identifier><identifier>DOI: 10.1007/s10741-012-9354-7</identifier><identifier>PMID: 23135208</identifier><identifier>CODEN: HFREFC</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Cardiology ; Heart Failure - drug therapy ; Humans ; Infusions, Intravenous ; Medicine ; Medicine &amp; Public Health ; Sodium Potassium Chloride Symporter Inhibitors - administration &amp; dosage ; Sodium Potassium Chloride Symporter Inhibitors - adverse effects ; Sodium Potassium Chloride Symporter Inhibitors - therapeutic use ; Treatment Outcome</subject><ispartof>Heart failure reviews, 2014-03, Vol.19 (2), p.237-246</ispartof><rights>Springer Science+Business Media New York 2012</rights><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-31f6489519fc094967d1dc269bc8738d84c6350b2a030a105d324aabb7d6f6393</citedby><cites>FETCH-LOGICAL-c438t-31f6489519fc094967d1dc269bc8738d84c6350b2a030a105d324aabb7d6f6393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23135208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leto, Laura</creatorcontrib><creatorcontrib>Aspromonte, Nadia</creatorcontrib><creatorcontrib>Feola, Mauro</creatorcontrib><title>Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review</title><title>Heart failure reviews</title><addtitle>Heart Fail Rev</addtitle><addtitle>Heart Fail Rev</addtitle><description>Intravenous loop diuretics are widely used to treat the symptoms and signs of fluid overload in acute heart failure (AHF). Although diuretic therapy is widely used and strongly recommended by most recent clinical guidelines, prospective studies and randomized clinical trials are lacking and so reliable evidence is missing about the best therapy in terms of doses and methods of administration. In addition, clinical efficacy and safety outcomes are often affected by the presence of contrasting evidence. The efficacy of loop diuretics is impaired by diuretic resistance characterized by a decreased diuretic and natriuretic effect. This review focuses on the current management of AHF with diuretic therapy. Continuous diuretic infusion seems to be a good choice, from a pharmacokinetic point of view, when fluid overload is refractory to conventional therapy. Some available evidence comparing bolus injection to continuous infusion of loop diuretics proved the latter to be an effective and safe method of administration. Continuous infusion seems to produce a constant plasmatic concentration of drug with a more uniform daily diuretic and natriuretic effect and a greater safety profile (fewer adverse events such as worsening renal failure, electrolyte imbalances, ototoxicity). The analyses of the published studies did not provide conclusive data about the effects on clinical outcomes (mortality, rate of hospital readmissions, length of hospital stay and adverse events). Furthermore, recent studies focus their attention on alternative strategies of fluid removal, such as vasopressin antagonists, adenosine antagonists and ultrafiltration but available data are often inconclusive.</description><subject>Cardiology</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - administration &amp; dosage</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - adverse effects</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1382-4147</issn><issn>1573-7322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kMtKxDAUhoMozjj6AG4k4Lqaa9O4k2G8wIAbXYc0F6dDp61Jq_TtzdBR3Lg6B873_wc-AC4xusEIiduIkWA4Q5hkknKWiSMwx1zQTFBCjtNOC5IxzMQMnMW4RQgxydApmBGKKSeomAO78r4y2oxQNxZG7V0_wtbDum07aKshuL4ysN-4oLsRVg3UZugdtM60u841UffOwo3ToYdeV3Xi76CGpq6a1FrD4D4r93UOTryuo7s4zAV4e1i9Lp-y9cvj8_J-nRlGiz6j2OeskBxLb5BkMhcWW0NyWZpC0MIWzOSUo5JoRJHGiFtKmNZlKWzucyrpAlxPvV1oPwYXe7Vth9CklwozWRDBCceJwhNlQhtjcF51odrpMCqM1N6rmryq5FXtvSqRMleH5qHcOfub-BGZADIBMZ2adxf-vP639RvVR4JL</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Leto, Laura</creator><creator>Aspromonte, Nadia</creator><creator>Feola, Mauro</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20140301</creationdate><title>Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review</title><author>Leto, Laura ; Aspromonte, Nadia ; Feola, Mauro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-31f6489519fc094967d1dc269bc8738d84c6350b2a030a105d324aabb7d6f6393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Cardiology</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - administration &amp; dosage</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - adverse effects</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leto, Laura</creatorcontrib><creatorcontrib>Aspromonte, Nadia</creatorcontrib><creatorcontrib>Feola, Mauro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Heart failure reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leto, Laura</au><au>Aspromonte, Nadia</au><au>Feola, Mauro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review</atitle><jtitle>Heart failure reviews</jtitle><stitle>Heart Fail Rev</stitle><addtitle>Heart Fail Rev</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>19</volume><issue>2</issue><spage>237</spage><epage>246</epage><pages>237-246</pages><issn>1382-4147</issn><eissn>1573-7322</eissn><coden>HFREFC</coden><abstract>Intravenous loop diuretics are widely used to treat the symptoms and signs of fluid overload in acute heart failure (AHF). Although diuretic therapy is widely used and strongly recommended by most recent clinical guidelines, prospective studies and randomized clinical trials are lacking and so reliable evidence is missing about the best therapy in terms of doses and methods of administration. In addition, clinical efficacy and safety outcomes are often affected by the presence of contrasting evidence. The efficacy of loop diuretics is impaired by diuretic resistance characterized by a decreased diuretic and natriuretic effect. This review focuses on the current management of AHF with diuretic therapy. Continuous diuretic infusion seems to be a good choice, from a pharmacokinetic point of view, when fluid overload is refractory to conventional therapy. Some available evidence comparing bolus injection to continuous infusion of loop diuretics proved the latter to be an effective and safe method of administration. Continuous infusion seems to produce a constant plasmatic concentration of drug with a more uniform daily diuretic and natriuretic effect and a greater safety profile (fewer adverse events such as worsening renal failure, electrolyte imbalances, ototoxicity). The analyses of the published studies did not provide conclusive data about the effects on clinical outcomes (mortality, rate of hospital readmissions, length of hospital stay and adverse events). Furthermore, recent studies focus their attention on alternative strategies of fluid removal, such as vasopressin antagonists, adenosine antagonists and ultrafiltration but available data are often inconclusive.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23135208</pmid><doi>10.1007/s10741-012-9354-7</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1382-4147
ispartof Heart failure reviews, 2014-03, Vol.19 (2), p.237-246
issn 1382-4147
1573-7322
language eng
recordid cdi_proquest_journals_1498275251
source Springer Link
subjects Cardiology
Heart Failure - drug therapy
Humans
Infusions, Intravenous
Medicine
Medicine & Public Health
Sodium Potassium Chloride Symporter Inhibitors - administration & dosage
Sodium Potassium Chloride Symporter Inhibitors - adverse effects
Sodium Potassium Chloride Symporter Inhibitors - therapeutic use
Treatment Outcome
title Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A03%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20loop%20diuretic%20therapy%20in%20acute%20decompensated%20heart%20failure:%20a%20clinical%20review&rft.jtitle=Heart%20failure%20reviews&rft.au=Leto,%20Laura&rft.date=2014-03-01&rft.volume=19&rft.issue=2&rft.spage=237&rft.epage=246&rft.pages=237-246&rft.issn=1382-4147&rft.eissn=1573-7322&rft.coden=HFREFC&rft_id=info:doi/10.1007/s10741-012-9354-7&rft_dat=%3Cproquest_cross%3E3219692821%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-31f6489519fc094967d1dc269bc8738d84c6350b2a030a105d324aabb7d6f6393%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1498275251&rft_id=info:pmid/23135208&rfr_iscdi=true